Transforming growth factor-beta superfamily ligand cluster (Activin A, Myostatin, GDF11, Activin B, BMP9) (TGF-beta ligand cluster)

This target group comprises a cluster of ligands within the Transforming Growth Factor-beta (TGF-beta) superfamily, including Activin A, Activin B, Myostatin (GDF8), Growth Differentiation Factor 11 (GDF11), and Bone Morphogenetic Protein 9 (BMP9). These secreted proteins are critical regulators of systemic homeostasis, influencing erythropoiesis, skeletal muscle growth, and vascular remodeling by signaling through Activin type II receptors (ActRIIA/B) and subsequent Smad transcription factors (UniProt P08476, O14793, O95390). In diseases such as pulmonary arterial hypertension (PAH), an imbalance occurs where overactive Activin and GDF signaling (Smad2/3) promotes pathological vascular remodeling, while BMP-mediated signaling (Smad1/5/8) is diminished (Hoeper et al., 2023, NEJM). Therapeutic strategies utilize 'ligand traps' like Sotatercept and Luspatercept, which are fusion proteins that sequester these circulating ligands to prevent receptor activation and restore signaling equilibrium (FDA, Winrevair Label; FDA, Reblozyl Label). By neutralizing these specific ligands, these drugs can improve red blood cell maturation in anemias or reverse vascular thickening in PAH. Clinical management of these targets requires careful monitoring of hematological parameters due to their potent effects on red blood cell production.

Other names

Activin receptor type II ligandsTGF-beta superfamily ligandsActivin A (Inhibin beta A)Myostatin (Growth differentiation factor 8)Growth differentiation factor 11 (GDF11)Activin B (Inhibin beta B)Bone morphogenetic protein 9 (BMP9/GDF2)

Ligand sequestration (trapping) using decoy receptors (e.g., ActRIIA-Fc or ActRIIB-Fc fusion proteins) to prevent these ligands from binding to their endogenous cell-surface receptors, thereby inhibiting Smad2/3 signaling and restoring balance with Smad1/5/8 signaling pathways.